SCHEDULE: Viking Global Updates Inhibrx Biosciences Stake

Viking Global Investors filed an amended Schedule 13G to reflect the retirement of David C. Ott from its reporting group.

Summary

• Viking Global Investors LP and associated entities reported beneficial ownership of 1,461,633 shares of Inhibrx Biosciences, Inc. common stock.
• This represents a 9.99% stake in the company.
• The filing serves as an amendment to remove David C. Ott as a reporting person following his retirement from Viking Global effective March 31, 2026.
• The holdings include 1,267,823 shares held directly by VGOP, 67,018 by KAVRA 104, 102,864 by VGOD, and 23,928 shares issuable upon warrant exercise.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting internal personnel changes at an investment firm rather than a change in investment thesis.

Positives

• The filing confirms the continued significant investment position of 9.99% by a major institutional investor.
• The reporting group maintains a stable ownership structure despite internal personnel changes.

Negatives

• The departure of a key executive committee member, David C. Ott, from the reporting group.

Risks

• The warrants held by VGOP are subject to a 9.99% ownership 'Blocker' provision, limiting immediate conversion and voting power.
• The reporting persons certify that the shares are held for investment purposes only and not to influence control, which may limit their ability to intervene in corporate strategy.

Future Outlook

The filing does not provide a forward-looking business outlook for the issuer, as it is a regulatory disclosure of beneficial ownership.

Industry Context

StockSavvy.ai notes that institutional filings of this nature are standard administrative updates. The continued 9.99% stake suggests that Viking Global remains committed to its position in the biotechnology sector despite internal leadership changes.

Comparison to Industry Standards

• The filing adheres to standard SEC requirements for institutional investors (13G) regarding changes in reporting groups.
• The use of 'Blocker' provisions on warrants is a standard practice for institutional investors to avoid triggering inadvertent control thresholds.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders should note the continued stability of the 9.99% institutional position.

Next Steps

• Continued monitoring of future 13G or 13D filings by Viking Global regarding their position in Inhibrx Biosciences.

Key Dates

Keywords

Inhibrx Biosciences, Viking Global Investors, Schedule 13G, Institutional Ownership, Biotech, INBX